Press
EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO)
Posted on February 17, 2021 by Riley NolanPROVIDENCE, RI, February 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU, India, and United States (funded by the EU and India) with the aim of developing next-generation influenza vaccines with better responsiveness, lower costs, ...Read moreEpiVax and EpiVax Therapeutics Advance COVID-19 Vaccine Program, EPV-CoV-19
Posted on December 31, 2020 by Annie De GrootPROVIDENCE, R.I., Dec. 31, 2020 /PRNewswire/ — EpiVax (“EpiVax”) and EpiVax Therapeutics (“EVT”) today provide an update on the advancement of their peptide-based COVID-19 vaccine, EPV-CoV-19. EPV-CoV-19, a T cell epitope-based vaccine designed by EpiVax’s scientists in February 2020 and licensed to EVT in August 2020, has completed IND-enabling preclinical validation studies and is making steady progress towards a clinical trial, anticipated in ...Read moreEpiVax Advances “PANDA” Peptide Therapeutic Immunogenicity Screening Program
Posted on December 29, 2020 by Annie De GrootPROVIDENCE, R.I., Dec. 29, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today provides an update on the advancement of the company’s peptide therapeutic immunogenicity assessment program. The PANDA (Peptide Abbreviated New Drug Application) immunogenicity assessment program was originally developed for screening generic peptide drugs and their impurities following the publication of the ANDA draft guidance by the Food and Drug Administration ...Read moreEpiVax Reports Record Year for Immunogenicity Screening Toolkit (ISPRI)
Posted on December 15, 2020 by Annie De GrootPROVIDENCE, RI, December 15, 2020 /PRNewswire/ — EpiVax, Inc. reports a record-breaking year for the “ISPRI” immunogenicity screening toolkit. More pharmaceutical and biotechnology companies signed new and continuing licenses for access to the toolkit in 2020 than ever before in the company’s twenty-two years of business. EpiVax first developed the ISPRI toolkit in 2006 to enable ...Read moreFDA Awards $1.1M Contract to CUBRC and EpiVax for Validation of New Immunoinformatic Tool for Prospective Immunogenicity Assessment of Peptide Drugs and Their Impurities
Posted on October 22, 2020 by Annie De GrootPROVIDENCE, RI, October 22, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) and CUBRC, Inc. (“CUBRC”) announced today that they have been awarded a two-year, $1.1 million contract from the Office of Generic Drugs (OGD) in the Center of Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA) in response to a Broad Agency ...Read moreEpiVax Announces Licensing of COVID-19 Vaccine Candidate to EpiVax Therapeutics
Posted on August 25, 2020 by Annie De GrootPROVIDENCE, RI, August 24, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”), a Rhode Island-based company and recognized leader in the field of computational vaccinology, today announced it has out-licensed its COVID-19 vaccine candidate, EPV-CoV-19, to EpiVax Therapeutics (“EVT”), a New York-based company previously named EpiVax Oncology. Scientists at EpiVax designed EPV-CoV-19 – a peptide-based, epitope-driven vaccine – ...Read moreSix months in, are we any closer to a vaccine?
Posted on July 24, 2020 by Annie De GrootSix months in, are we any closer to a vaccine?Read morePress Release: EpiVax Announces Licensing of Immunogenicity Screening Toolkit, ISPRI, to AbCellera
Posted on June 8, 2020 by Annie De GrootPress Release: EpiVax Announces Licensing of Immunogenicity Screening Toolkit, ISPRI, to AbCelleraRead morePress Release: Intravacc and EpiVax team up in development of COVID-19 emerging vaccine
Posted on June 2, 2020 by Annie De GrootPress Release: Intravacc and EpiVax team up in development of COVID-19 emerging vaccineRead morePress Release: Pacific GeneTech Partners With EpiVax on a Novel Vaccine Approach for ASF
Posted on May 1, 2020 by Annie De GrootHONG KONG, May 1, 2020 (Newswire.com) – Pacific GeneTech (PGT), a biologics company that develops and commercializes next-generation vaccines for areas of high unmet or underserved needs in animal health and food safety, is collaborating with Rhode Island-based EpiVax, an informatics & immunology company, to develop a novel vaccine for African Swine Fever. African Swine Fever (ASF) ...Read morePress Release: Entos Pharmaceuticals partners with EpiVax to develop a pan-coronavirus DNA vaccine
Posted on April 28, 2020 by Annie De GrootEDMONTON, Alberta, April 28, 2020 — Entos Pharmaceuticals (Entos), a healthcare biotechnology company that develops next generation nucleic acid medicines using the Fusogenix drug delivery platform, today announced a collaboration with EpiVax, Inc. (EpiVax), a world leading informatics and immunology biotechnology company with a proven track record in vaccine development. This partnership will combine the Entos ...Read morePress Release: PharmaJet partners with Immunomic Therapeutics and EpiVax to develop and deliver COVID-19 Vaccine
Posted on April 15, 2020 by Annie De GrootPress Release: PharmaJet partners with Immunomic Therapeutics and EpiVax to develop and deliver COVID-19 VaccineRead morePress Release: Immunomic Therapeutics Forms Collaboration with EpiVax and PharmaJet to Develop Novel Vaccine Candidate Against COVID-19 Using its Investigational UNITE Platform
Posted on April 9, 2020 by Annie De GrootRead the original BusinessWire publication here. ROCKVILLE, MD, PROVIDENCE, RI, and GOLDEN, CO, April 09, 2020 — Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it is developing a nucleic acid vaccine candidate against COVID-19 leveraging its investigational UNITE platform for prevention of ...Read morePress Release: EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countries
Posted on April 7, 2020 by Annie De GrootPress Release: EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing CountriesRead moreProvidence biotech firm is working on a coronavirus vaccine – Boston Globe interview
Posted on March 30, 2020 by Annie De GrootProvidence biotech firm is working on a coronavirus vaccine - Boston Globe interviewRead more
Join our newsletter
We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content. Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.